{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T23:24:35Z","timestamp":1786922675555,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100013302","name":"King Abdullah International Medical Research Center","doi-asserted-by":"publisher","award":["No. RC20\/576\/R"],"award-info":[{"award-number":["No. RC20\/576\/R"]}],"id":[{"id":"10.13039\/501100013302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-51843-x","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:36:06Z","timestamp":1779204966000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Select novel small-molecule uPA potential inhibitors as anti-cancer agents against breast cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Nadin","family":"Almosnid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imadul","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizwan","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shatha","family":"Algheribe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00a0Rabih","family":"O.\u00a0Al-Kaysi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Huwaizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reham A.","family":"Abed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalal","family":"Aldeghaither","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohmed","family":"Boudjelal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nosaibah","family":"Samman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimer","family":"Mehyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norah","family":"Alruwaili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"issue":"9","key":"51843_CR1","first-page":"1087","volume":"29","author":"Z Werb","year":"1996","unstructured":"Werb, Z., Ashkenas, J., MacAuley, A. & Wiesen, J. F. Extracellular matrix remodeling as a regulator of stromal-epithelial interactions during mammary gland development, involution and carcinogenesis. Braz. J. Med Biol. Res. 29(9), 1087\u201397 (1996) (PubMed PMID: 9181050).","journal-title":"Braz. J. Med Biol. Res."},{"issue":"1","key":"51843_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.2174\/156800909787314002","volume":"9","author":"S Ulisse","year":"2009","unstructured":"Ulisse, S., Baldini, E., Sorrenti, S. & D\u2019Armiento, M. The urokinase plasminogen activator system: a target for anti-cancer therapy. CCDT 9(1), 32\u201371. https:\/\/doi.org\/10.2174\/156800909787314002 (2009).","journal-title":"CCDT"},{"issue":"14","key":"51843_CR3","doi-asserted-by":"publisher","first-page":"23099","DOI":"10.18632\/oncotarget.15485","volume":"8","author":"D Brungs","year":"2017","unstructured":"Brungs, D. et al. The urokinase plasminogen activation system in gastroesophageal cancer: a systematic review and meta-analysis. Oncotarget 8(14), 23099\u2013109. https:\/\/doi.org\/10.18632\/oncotarget.15485 (2017).","journal-title":"Oncotarget"},{"issue":"7","key":"51843_CR4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrc2400","volume":"8","author":"DR Croucher","year":"2008","unstructured":"Croucher, D. R., Saunders, D. N., Lobov, S. & Ranson, M. Revisiting the biological roles of PAI2 (SERPINB2) in cancer. Nat. Rev. Cancer. 8(7), 535\u201345. https:\/\/doi.org\/10.1038\/nrc2400 (2008).","journal-title":"Nat. Rev. Cancer."},{"issue":"30","key":"51843_CR5","doi-asserted-by":"publisher","first-page":"4288","DOI":"10.1038\/onc.2017.63","volume":"36","author":"NLE Harris","year":"2017","unstructured":"Australian Pancreatic Cancer Genome Initiative et al. SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer. Oncogene 36(30), 4288\u201398. https:\/\/doi.org\/10.1038\/onc.2017.63 (2017).","journal-title":"Oncogene"},{"key":"51843_CR6","doi-asserted-by":"publisher","unstructured":"Yang JL, Seetoo D qiang, Wang Y, Ranson M, Berney CR, Ham JM, et al. Urokinase-type plasminogen activator and its receptor in colorectal cancer: Independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets. Int J Cancer.Sep 20;89(5):431\u20139. https:\/\/doi.org\/10.1002\/1097-0215(20000920)89:5%3C431::AID-IJC6%3E3.0.CO;2-V(2000).","DOI":"10.1002\/1097-0215(20000920)89:5%3C431::AID-IJC6%3E3.0.CO;2-V"},{"issue":"7","key":"51843_CR7","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.clinbiochem.2004.05.013","volume":"37","author":"MJ Duffy","year":"2004","unstructured":"Duffy, M. J. & Duggan, C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin. Biochem. 37(7), 541\u20138. https:\/\/doi.org\/10.1016\/j.clinbiochem.2004.05.013 (2004).","journal-title":"Clin. Biochem."},{"issue":"33","key":"51843_CR8","doi-asserted-by":"publisher","first-page":"5287","DOI":"10.1200\/JCO.2007.14.2364","volume":"25","author":"L Harris","year":"2007","unstructured":"Harris, L. et al. American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. JCO 25(33), 5287\u2013312. https:\/\/doi.org\/10.1200\/JCO.2007.14.2364 (2007).","journal-title":"JCO"},{"key":"51843_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.breast.2019.05.007","volume":"46","author":"CF Singer","year":"2019","unstructured":"Singer, C. F. et al. Stromal coexpression of uPA\/PAI-1 protein predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer. Breast 46, 101\u20137. https:\/\/doi.org\/10.1016\/j.breast.2019.05.007 (2019).","journal-title":"Breast"},{"issue":"2","key":"51843_CR10","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ctrv.2007.10.005","volume":"34","author":"K Dass","year":"2008","unstructured":"Dass, K., Ahmad, A., Azmi, A. S., Sarkar, S. H. & Sarkar, F. H. Evolving role of uPA\/uPAR system in human cancers. Cancer Treat. Rev. 34(2), 122\u201336. https:\/\/doi.org\/10.1016\/j.ctrv.2007.10.005 (2008).","journal-title":"Cancer Treat. Rev."},{"key":"51843_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.mbplus.2023.100137","volume":"19\u201320","author":"A Micalet","year":"2023","unstructured":"Micalet, A. et al. Urokinase-type plasminogen activator (uPA) regulates invasion and matrix remodelling in colorectal cancer. Matrix Biol. Plus 19\u201320, 100137. https:\/\/doi.org\/10.1016\/j.mbplus.2023.100137 (2023).","journal-title":"Matrix Biol. Plus"},{"issue":"2","key":"51843_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbapap.2020.140562","volume":"1869","author":"N Sevillano","year":"2021","unstructured":"Sevillano, N. et al. Structure of an affinity-matured inhibitory recombinant fab against urokinase plasminogen activator reveals basis of potency and specificity. Biochimica. et Biophysica. Acta (BBA) - Proteins Proteomics 1869(2), 140562. https:\/\/doi.org\/10.1016\/j.bbapap.2020.140562 (2021).","journal-title":"Biochimica. et Biophysica. Acta (BBA) - Proteins Proteomics"},{"issue":"18","key":"51843_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202203356","volume":"12","author":"Z Rao","year":"2023","unstructured":"Rao, Z. et al. Engineered macrophages\u2010based uPA\u2010scavenger load gemcitabine to prompt robust treating cancer metastasis. Adv. Healthc. Mater. 12(18), 2203356. https:\/\/doi.org\/10.1002\/adhm.202203356 (2023).","journal-title":"Adv. Healthc. Mater."},{"issue":"5","key":"51843_CR14","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/med.21308","volume":"34","author":"AH Mekkawy","year":"2014","unstructured":"Mekkawy, A. H., Pourgholami, M. H. & Morris, D. L. Involvement of urokinase\u2010type plasminogen activator system in cancer: an overview. Med. Res. Rev. 34(5), 918\u201356. https:\/\/doi.org\/10.1002\/med.21308 (2014).","journal-title":"Med. Res. Rev."},{"issue":"21","key":"51843_CR15","first-page":"6101","volume":"52","author":"JA Foekens","year":"1992","unstructured":"Foekens, J. A. et al. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res. 52(21), 6101\u20135 (1992) (PubMed PMID: 1394237).","journal-title":"Cancer Res."},{"issue":"1","key":"51843_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-10-270","volume":"10","author":"Y Ding","year":"2012","unstructured":"Ding, Y. et al. u-PA inhibitor amiloride suppresses peritoneal metastasis in gastric cancer. World J. Surg. Oncol. 10(1), 270. https:\/\/doi.org\/10.1186\/1477-7819-10-270 (2012).","journal-title":"World J. Surg. Oncol."},{"key":"51843_CR17","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.14.3.535","author":"H Miyake","year":"1999","unstructured":"Miyake, H., Hara, I., Yamanaka, K., Arakawa, S. & Kamidono, S. Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. Int. J. Oncol. https:\/\/doi.org\/10.3892\/ijo.14.3.535 (1999).","journal-title":"Int. J. Oncol."},{"issue":"1","key":"51843_CR18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1152\/physrev.1993.73.1.161","volume":"73","author":"P Mignatti","year":"1993","unstructured":"Mignatti, P. & Rifkin, D. B. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 73(1), 161\u201395. https:\/\/doi.org\/10.1152\/physrev.1993.73.1.161 (1993).","journal-title":"Physiol. Rev."},{"key":"51843_CR19","doi-asserted-by":"publisher","unstructured":"K Dan\u00f8 L Skriver. Plasminogen Activators, Tissue Degradation, and Cancer. In: Advances in Cancer Research [Internet]. Elsevier; 1985 [cited 2025 Oct 8]. p. 139\u2013266. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065230X08600287https:\/\/doi.org\/10.1016\/S0065-230X(08)60028-7","DOI":"10.1016\/S0065-230X(08)60028-7"},{"issue":"4","key":"51843_CR20","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/ijc.2910610419","volume":"61","author":"A Billstr\u00f6m","year":"1995","unstructured":"Billstr\u00f6m, A., Hartley\u2010Asp, B., Lecander, I., Batra, S. & \u00c5stedt, B. The urokinase inhibitor p \u2010aminobenzamidine inhibits growth of a human prostate tumor in scid mice. Int. J. Cancer 61(4), 542\u20137. https:\/\/doi.org\/10.1002\/ijc.2910610419 (1995).","journal-title":"Int. J. Cancer"},{"issue":"1","key":"51843_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1006\/bbrc.1995.1465","volume":"209","author":"M Kawada","year":"1995","unstructured":"Kawada, M. & Umezawa, K. Suppression of in vitro invasion of human fibrosarcoma cells by a Leupeptin analog inhibiting the urokinase-plasmin system. Biochem. Biophys. Res. Commun. 209(1), 25\u201330. https:\/\/doi.org\/10.1006\/bbrc.1995.1465 (1995).","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"51843_CR22","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1158\/0008-5472.CAN-05-3636","volume":"66","author":"N Khan","year":"2006","unstructured":"Khan, N., Afaq, F., Saleem, M., Ahmad, N. & Mukhtar, H. Targeting multiple signaling pathways by green tea polyphenol (\u2212)-Epigallocatechin-3-Gallate. Cancer Res. 66(5), 2500\u20135. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-3636 (2006).","journal-title":"Cancer Res."},{"issue":"6","key":"51843_CR23","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1021\/acs.molpharmaceut.3c00055","volume":"20","author":"AA Kumar","year":"2023","unstructured":"Kumar, A. A., Vine, K. L. & Ranson, M. Recent advances in targeting the urokinase plasminogen activator with nanotherapeutics. Mol. Pharm. 20(6), 2766\u201380. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c00055 (2023).","journal-title":"Mol. Pharm."},{"issue":"4","key":"51843_CR24","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/bjc.2013.62","volume":"108","author":"V Heinemann","year":"2013","unstructured":"Heinemann, V. et al. Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br. J. Cancer 108(4), 766\u201370. https:\/\/doi.org\/10.1038\/bjc.2013.62 (2013).","journal-title":"Br. J. Cancer"},{"key":"51843_CR25","unstructured":"WILEX AG Therapeutic Target MESUPRON\u00ae. Available from: https:\/\/web.archive.org\/web\/20150103035314\/http:\/\/www.wilex.de\/portfolio-English\/mesupron\/therapeutic-Target (2015)."},{"issue":"21","key":"51843_CR26","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1016\/S0960-894X(99)00541-7","volume":"9","author":"J St\u00fcrzebecher","year":"1999","unstructured":"St\u00fcrzebecher, J. et al. 3-Amidinophenylalanine-based inhibitors of urokinase. Bioorg. Med. Chem. Lett. 9(21), 3147\u201352. https:\/\/doi.org\/10.1016\/S0960-894X(99)00541-7 (1999).","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"1","key":"51843_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2174\/1573406053402569","volume":"1","author":"G Abbenante","year":"2005","unstructured":"Abbenante, G. & Fairlie, D. Protease inhibitors in the clinic. MC 1(1), 71\u2013104. https:\/\/doi.org\/10.2174\/1573406053402569 (2005).","journal-title":"MC"},{"issue":"04","key":"51843_CR28","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1160\/TH04-11-0712","volume":"93","author":"B Setyono-Han","year":"2005","unstructured":"Setyono-Han, B. et al. Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1. Thromb. Haemost. 93(04), 779\u201386. https:\/\/doi.org\/10.1160\/TH04-11-0712 (2005).","journal-title":"Thromb. Haemost."},{"issue":"2","key":"51843_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1159\/000151736","volume":"3","author":"JE Meyer","year":"2008","unstructured":"Meyer, J. E. et al. The oral serine protease inhibitor WX-671 &ndash; first experience in patients with advanced head and neck carcinoma. Breast Care 3(2), 5\u20135. https:\/\/doi.org\/10.1159\/000151736 (2008).","journal-title":"Breast Care"},{"issue":"20","key":"51843_CR30","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1016\/j.bmcl.2018.09.001","volume":"28","author":"I Islam","year":"2018","unstructured":"Islam, I. et al. Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis. Bioorg. Med. Chem. Lett. 28(20), 3372\u20135. https:\/\/doi.org\/10.1016\/j.bmcl.2018.09.001 (2018).","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"19","key":"51843_CR31","doi-asserted-by":"publisher","first-page":"5712","DOI":"10.1016\/j.bmcl.2009.08.008","volume":"19","author":"CW West","year":"2009","unstructured":"West, C. W. et al. Identification of orally bioavailable, non-amidine inhibitors of urokinase plasminogen activator (uPA). Bioorg. Med. Chem. Lett. 19(19), 5712\u20135. https:\/\/doi.org\/10.1016\/j.bmcl.2009.08.008 (2009).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"51843_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3812-5","author":"R Ali","year":"2017","unstructured":"Ali, R. et al. Isolation and characterization of a new naturally immortalized human breast carcinoma cell line, KAIMRC1. BMC Cancer https:\/\/doi.org\/10.1186\/s12885-017-3812-5 (2017).","journal-title":"BMC Cancer"},{"issue":"6","key":"51843_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cells10061303","volume":"10","author":"R Ali","year":"2021","unstructured":"Ali, R. et al. Isolation and establishment of a highly proliferative, cancer stem cell-like, and naturally immortalized triple-negative breast cancer cell line, KAIMRC2. Cells 10(6), 1303. https:\/\/doi.org\/10.3390\/cells10061303 (2021).","journal-title":"Cells"},{"issue":"4","key":"51843_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063038","volume":"8","author":"LJ Leon","year":"2013","unstructured":"Leon, L. J., Pasupuleti, N., Gorin, F. & Carraway, K. L. A cell-permeant amiloride derivative induces caspase-independent, AIF-mediated programmed necrotic death of breast cancer cells. PLoS ONE 8(4), e63038. https:\/\/doi.org\/10.1371\/journal.pone.0063038 (2013).","journal-title":"PLoS ONE"},{"issue":"6b","key":"51843_CR35","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1111\/j.1582-4934.2008.00272.x","volume":"12","author":"HK Madhyastha","year":"2008","unstructured":"Madhyastha, H. K., Radha, K. S., Nakajima, Y., Omura, S. & Maruyama, M. uPA dependent and independent mechanisms of wound healing by C-phycocyanin. J. Cell. Mol. Med. 12(6b), 2691\u2013703. https:\/\/doi.org\/10.1111\/j.1582-4934.2008.00272.x (2008).\u00a0 (PubMed PMID: 18266963; PubMed Central PMCID: PMC3828884).","journal-title":"J. Cell. Mol. Med."},{"key":"51843_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00024","author":"N Mahmood","year":"2018","unstructured":"Mahmood, N., Mihalcioiu, C. & Rabbani, S. A. Multifaceted role of the urokinase-type plasminogen activator (uPA) and its receptor (uPAR): diagnostic, prognostic, and therapeutic applications. Front. Oncol. https:\/\/doi.org\/10.3389\/fonc.2018.00024 (2018).","journal-title":"Front. Oncol."},{"issue":"12","key":"51843_CR37","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1038\/sj.emboj.7601173","volume":"25","author":"LR Lund","year":"2006","unstructured":"Lund, L. R. et al. Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice. EMBO J. 25(12), 2686\u201397. https:\/\/doi.org\/10.1038\/sj.emboj.7601173 (2006). (PubMed PMID: 16763560; PubMed Central PMCID: PMC1500865).","journal-title":"EMBO J."},{"issue":"9","key":"51843_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012746","volume":"5","author":"A J\u00f6gi","year":"2010","unstructured":"J\u00f6gi, A. et al. Neutralisation of uPA with a monoclonal antibody reduces plasmin formation and delays skin wound healing in tPA-deficient mice. PLoS One 5(9), e12746. https:\/\/doi.org\/10.1371\/journal.pone.0012746 (2010).","journal-title":"PLoS One"},{"issue":"12","key":"51843_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051303","volume":"7","author":"Y Shen","year":"2012","unstructured":"Shen, Y. et al. Mice deficient in Urokinase-Type Plasminogen Activator have delayed healing of tympanic membrane perforations. PLoS. One 7(12), e51303. https:\/\/doi.org\/10.1371\/journal.pone.0051303 (2012).","journal-title":"PLoS. One"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51843-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51843-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51843-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T22:31:33Z","timestamp":1786919493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51843-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["51843"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-51843-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this study was obtained from the Institutional Review Board (IRB) at the King Abdullah International Medical Research Center (KAIMRC).","order":2,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"25542"}}